ASH 2021
Part I: Pola-R-CHP - possible new standard in 1st line?
POLARIX
ASH 2021
Part I: Pola-R-CHP - possible new standard in 1st line?
ZUMA-7, TRANSFORM, Belinda
ASH 2021
Part II: CAR-T cells - all over the field data for…
ZUMA-7, BELINDA, TRANSFORM
ASH 2021
axi-cel, tisa-cel, liso-cel: New CAR-T options for R/R…
ASH 2021
Prevention of CNS relapse after R-CHOP
POLARIX
ASH 2021
pola-R-CHP vs. R-CHOP: a new standard?
BELINDA
ASH 2021
Tisa-cel - new CAR-T option for R/R aNHL
ZUMA‑7
ASH 2021
Axi-cel - new standard for r/r LBCL patients?
ASH 2021
HD-MTX does not lower SCNS rates in high-risk patients
ZUMA-7, BELINDA, TRANSFORM
ASH 2021
Axi-Cel I Tisa-Cel I Liso-Cel: Drei neue CAR-T-Optionen…
ZUMA‑7
ASH 2021
Axi Cel: un nuovo standard nel DLBCL recidivato o…
ASH 2021
La prevenzione della recidiva a carico del sistema…
POLARIX
ASH 2021
pola-R-CHP vs. R-CHOP: Neuer Standard?
MCL R2 Elderly
ASH 2021
Part I: Potential change in first-line treatment?
BRUIN
ASH 2021
Part II: The white elephant in the room - BTKi
ASH 2021
Encouraging real world safety and efficacy data of…
BRUIN
ASH 2021
Next generation BTKI Pirtobrutinib
BRUIN, BRUIN MCL-321
ASH 2021
Pirtobrutinib shows promising efficacy and safety in…
BRUIN
ASH 2021
Pirtobrutinib - promising agent moving forward
MCL R2 Elderly
ASH 2021
Low-dose lenalidomide added to rituximab maintenance in…
MCL R2 Elderly
ASH 2021
Maintenance with Rituximab-Lenalidomid (R2)
ASH 2021
Glofitamab SUD as monotherapy after Gpt induced high…
MCL R2 Elderly
ASH 2021
Focus on maintenance is critical in MCL
MCL Younger
ASH 2021
HiDAC-containing induction before ASCT substantially…
MCL R2 Elderly
ASH 2021
Ruolo del mantenimento con R2 nel linfoma mantellare
MCL Younger
ASH 2021
La inducción con citarabina a dosis altas antes del…
MCL R2 Elderly
ASH 2021
Rituximab-Lenalidomid Erhaltungstherapie (R2)
BRUIN, BRUIN MCL-321
ASH 2021
Pirtobrutinib es eficaz y seguro en pacientes muy…
BRUIN
ASH 2021
Pirtobrutinib: Neuer, nicht-kovalenter BTKi
MCL R2 Elderly
ASH 2021
Añadir lenalidomida a dosis bajas a rituximab en el…
ASH 2021
Eficacia y seguridad de brexu-cel en pacientes con LCM…
ASH 2021
Part II: Bi-specific antibodies as an attractive agent
ZUMA-5, ELARA
ASH 2021
Part I: CAR-T cells on the way
FOLL12
ASH 2021
First-line options and RM
ASH 2021
Novel immunotherapy approaches to R/R follicular…
FOLL12
ASH 2021
MRD monitoring in follicular lymphoma is extremely…
ASH 2021
Active new therapy for 3L+ R/R FL
FOLL12
ASH 2021
Rituximab-Erhaltung nach ICT bleibt Standard
ASH 2021
Mosunetuzumab + Lenalidomid beim r/r FL
FOLL12
ASH 2021
Ruolo del monitoraggio della malattia minima residua…
BRUIN CLL, SEQUOIA
ASH 2021
Part I: Promising data in CLL
CLL13 / GAIA, FLAIR
ASH 2021
Part II: More data to wait for
BRUIN
ASH 2021
Pirtobrutinib - promising efficacy in heavily…
SEQUOIA
ASH 2021
BTKi as new option for untreated CLL/SLL patients
iStopMM
ASH 2021
Big data on smoldering multiple myeloma: the iStopMM…
CASSIOPEIA, Griffin, GMMG-HD7, HOVON 143, etc.
ASH 2021
NDMM: On the way to cure?
MajesTEC-1, TRIMM-2, Magnetismm-1, MonumenTAL-1
ASH 2021
The immunotherapy tsunami continues - bispecific…
CARTITUDE-1, CARTITUDE-2
ASH 2021
The immunotherapy tsunami continues - CAR-T cells
Griffin; CASSIOPEIA; MANHATTAN
ASH 2021
The future is already here - the use of antibodies in…
GMMG-HD7
ASH 2021
Quadruple regimens for NDMM
GMMG-HD6 Trial
ASH 2021
No benefit for elotuzumab in NDMM
HOVON 143
ASH 2021
Triplet therapie in elderly patients
Griffin
ASH 2021
PFS separation in the Griffin trial
CASSIOPEIA, Griffin
ASH 2021
Quadruple therapy - the treatment of choice in NDMM
Muknine
ASH 2021
Positive results for high-risk myeloma from the UK
Griffin, CASSIOPEIA, MANHATTAN
ASH 2021
The future is already here - the use of antibodies in…
CASSIOPEIA, Griffin
ASH 2021
Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei…
Griffin
ASH 2021
PFS separation in the Griffin trial
GMMG-HD6 Trial, GMMG-HD7 Trial
ASH 2021
Isatuximab + RVd erfogreich, Elotuzumab nicht
BELLINI
ASH 2021
Personalized medicine with venetoclax
MonumenTAL-1, TRIMM-2
ASH 2021
talquetamab & cevostamab: bispecific antibodies beyond…
MajesTEC-1; Magnetismm-1; CARTITUDE-1
ASH 2021
New bispecific antibodies and CAR-T cells for RRMM…
MonumenTAL-1
ASH 2021
Not another BCMA drug
Magnetismm-1
ASH 2021
Elranatamab - a new bispecific antibody in RRMM
CARTITUDE-1
ASH 2021
Is CAR-T cell treatment better in heavly pretreated…
MajesTEC-1
ASH 2021
Update on bispecific antibody teclistamab
CONPET
ASH 2021
KRd consolidation reverses PET positivity in 1/3 of the…
ASH 2021
TAK-573 - a really new mechanism of treatment in…
CARTITUDE-1
ASH 2021
cilta-cel highly effective in heavily pretreated…
CARTITUDE-1
ASH 2021
cilta-cel: early, deep and durable responses in heavily…
CARTITUDE-1
ASH 2021
cilta-cel hoch erfolgreich bei stark vorbehandelten…
MonumenTAL-1, Magnetismm-3
ASH 2021
CAR-T oder bispezifische MoAk in der Rezidivtherapie -…
MajesTEC-1
ASH 2021
Bispezifischer Antikörper Teclistamab beim r/r MM
MonumenTAL-1, TRIMM-2
ASH 2021
Talquetamab und Cevostamab: Neue bispezifische Ak…
CONPET
ASH 2021
KRd consolidation reverses PET-positivity in 1/3 of the…
ASH 2021
TAK-573 - a really new mechanism of treatment in…
CARTITUDE-1
ASH 2021
cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen…
MajesTEC-1, Magnetismm-1, CARTITUDE-1
ASH 2021
New bispecific antibodies and CAR-T cells for RRMM…
iStopMM
ASH 2021
New reference values for light chains in multiple…
iStopMM
ASH 2021
Myeloma precursor disease 2021
iStopMM
ASH 2021
MGUS and COVID-19 risk
iStopMM
ASH 2021
Myeloma precurser disease 2021
iStopMM, PROMISE
ASH 2021
Prävalenz und Risikostratifikation beim SMM
iStopMM
ASH 2021
New reference values for light chains in multiple…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!